In the context of glaucoma, the use of IOP-lowering eye drops remains the main threat to the ocular surface, says CU Department of Ophthalmology assistant professor Kaleb Abbott, OD, MS, FAAO. Prostaglandins upregulate matrix metalloproteinases, compromising the membrane integrity of conjunctival cells and damaging corneal epithelial cells.